Ovarian Cancer

A recent study found Avastin to be more effective in treating certain types of ovarian cancers.

Black and Latina women with ovarian cancer were less likely than white women to enroll in hospice care within the last 30 days.

Ovarian cancer is rare, and receives less research funding than some other cancers.

The investigational compound targets overexpressed folate receptor-alpha.

After eight years with no new treatments for ovarian cancer, PARP inhibitors and anti-angiogenics are benefiting patients.

Shana Wingo, M.D., discussed advancements being made in the field of surgery for patients with gynecologic cancers.

A recent study examined common co-morbidities, such as diabetes, heart disease and hypertension, and their effects on ovarian cancer survival.

Shana Wingo, M.D., discusses surgery's changing role in the treatment of ovarian cancer.

PARP inhibitors like Rubraca and Lynparza continue to shape the treatment landscape of ovarian cancer.

The FDA has approved Zejula (niraparib) for treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in the maintence setting.

Results from a randomized trial suggest maintenance chemotherapy after debulking surgery and adjuvant platinum-based chemotherapy do not improve overall survival rates among women with ovarian cancer who had achieved remission.

Hormonal maintenance therapy may be able to improve PFS rates for some patients with ovarian cancer, according to a recent study.

Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study.

Improved overall survival (OS) was achieved in patients with BRCA-proficient ovarian cancer who were treated with a carboplatin desensitization regimen.